Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eplerenone to Prevent Myocardial Fibrosis in Congenital Heart Disease

Trial Profile

Eplerenone to Prevent Myocardial Fibrosis in Congenital Heart Disease

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 11 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Heart disorders
  • Focus Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 16 Feb 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Dec 2014 Planned End Date changed from 1 Jan 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top